Explore the latest developments concerning Valneva to lay.
Transcript: Valneva Q1 2026 Earnings Conference Call
On Wednesday, Valneva (NASDAQ:VALN) discussed first-quarter financial results during its earnings call. The full transcript is provided below.
This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation.
The full earnings call is available at https://edge.media-server.com/mmc/p/xbkzgkz7
Valneva SE reported first-quarter revenues of approximately €30 million, with a decline from the previous year attributed to changes in business setup, supply phasing, and one-off expenses.
The company is focused on cash management and announced a workforce reduction of 10-15% to achieve a 25-35% reduction in operating expenses.
Valneva’s Q1 Revenue Takes a 40% Hit From Restructuring, but Lyme Vaccine and Shigella Data Loom L
Valneva's Q1 2026 revenue fell nearly 40% to €30.9M, net loss widened to €32.1M, but Lyme vaccine LB6V with >70% efficacy in phase 3 offers hope. Stock down ~34% YTD.
Valneva’s pipeline provided a much-needed bright spot during a quarter marked by sliding revenue and a deepening net loss. The biotechnology company and its partner Pfizer are preparing regulatory submissions for the experimental Lyme disease vaccine LB6V after phase 3 data showed efficacy above 70% in people aged five and older, with no safety concerns flagged. The achievement stands in stark contrast to Valneva’s first quarter financial results, where the top line fell sharply.
Magcubic 650ANSI L018 Projector 4K Native 1080P Auto Focus & Keystone Correction Android11 BT5.2 WIFI6 360° Portable Home Cinema
The dynamic landscape of current events often brings forth significant discussions. Monitoring these developments provides crucial insights.
For more detailed information, explore updates concerning Valneva to lay.
0 Comments